Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

75
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
75
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

28
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

6.0K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
6.0K
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

26
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
26
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

45
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...
45

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monoclonal Annular Lichenoid Dermatitis of Youth as a New Entity: A Case Report and Review of the Literature.

International journal of molecular sciences·2026
Same author

Giant cutaneous melanoma presenting with hemorrhagic complications.

Acta dermatovenerologica Alpina, Pannonica, et Adriatica·2026
Same author

Two cases of bizarre acquired localised hyperpigmentation disorders - similar yet different diagnostic challenges: two case reports and a brief literature review.

Acta dermatovenerologica Alpina, Pannonica, et Adriatica·2025
Same author

NTRK3-rearranged spindle cell neoplasm of the skin: diagnostic pitfalls of an emerging entity, a case report.

Acta dermatovenerologica Alpina, Pannonica, et Adriatica·2025
Same author

Keratoelastoidosis Marginalis of the Hands: A Distinct Form of Palmoplantar Keratoderma.

Cureus·2024
Same author

A case of multiple autoimmune syndrome comprising autoimmune thyroid disease, vitiligo, morphea, and lichen sclerosus.

Acta dermatovenerologica Alpina, Pannonica, et Adriatica·2024

Related Experiment Video

Updated: May 4, 2026

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion
08:22

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion

Published on: March 20, 2017

10.6K

Insulin-induced localized lipoatrophy.

Vesna Breznik1, Rok Kokol, Boštjan Luzar

  • 1Department of Dermatology, University Medical Centre Maribor, Slovenia. Department of Dermatology, Medical Faculty, University of Maribor, Slovenia. Department of Pathology, Medical Faculty, University of Ljubljana, Slovenia. Corresponding author: breznikv@gmail.com.

Acta Dermatovenerologica Alpina, Pannonica, Et Adriatica
|December 17, 2013
PubMed
Summary

Insulin lipoatrophy is a rare skin issue causing fat loss at insulin injection sites. This case shows it occurring in a woman using insulin analogues for type 2 diabetes.

More Related Videos

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

3.7K
Fiber Type and Subcellular-Specific Analysis of Lipid Droplet Content in Skeletal Muscle
11:50

Fiber Type and Subcellular-Specific Analysis of Lipid Droplet Content in Skeletal Muscle

Published on: June 8, 2022

4.4K

Related Experiment Videos

Last Updated: May 4, 2026

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion
08:22

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion

Published on: March 20, 2017

10.6K
Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

3.7K
Fiber Type and Subcellular-Specific Analysis of Lipid Droplet Content in Skeletal Muscle
11:50

Fiber Type and Subcellular-Specific Analysis of Lipid Droplet Content in Skeletal Muscle

Published on: June 8, 2022

4.4K

Area of Science:

  • Endocrinology
  • Dermatology
  • Immunology

Background:

  • Insulin lipoatrophy is an uncommon immune complication of insulin therapy.
  • It manifests as localized subcutaneous fat atrophy at injection sites.
  • This condition is associated with diabetes mellitus management.

Observation:

  • A 62-year-old woman with type 2 diabetes mellitus was evaluated.
  • She had used insulin analogues detemir and aspart for six years.
  • The patient presented with localized lipoatrophy on her abdomen.

Findings:

  • The patient developed insulin lipoatrophy.
  • The condition was associated with long-term use of insulin detemir and aspart.
  • Abdominal fat atrophy was the presenting sign.

Implications:

  • This case underscores the potential for insulin lipoatrophy with specific insulin analogues.
  • Awareness is crucial for early diagnosis and management of injection site complications.
  • Further research into the immunologic mechanisms of insulin lipoatrophy is warranted.